Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications.


Amphetamine or methylphenidate are first-line options for treating attention-deficit/hyperactivity disorder (ADHD). Deviations from suggested routes of administration such as crushing, chewing, intravenous administration, or snorting stimulant medication may alter the release rate, absorption, and bioavailability of the active drug. Additionally, the… (More)
DOI: 10.1080/00325481.2016.1218259


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics